AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.34
−0.19%Aug 11, 2026, 20:01 UTC
Aquestive Therapeutics reported its financial results for the second quarter ended June 30, 2026.
Aug 10, 2026, 11:00 UTC
Aquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for its Anaphylm (dibutepinephrine) sublingual film, supporting a planned NDA resubmission to the FDA in Q3 2026.